Breaking Resistance, Shaping the Future | Research Voices (Episode 4)

Prof. A. Thomas Look Reflects on Evolutionary Resistance, Transgenic Zebrafish Models, and the Future of Pediatric Oncology

As part of Breaking Resistance, Shaping the Future, a scientific series celebrating the eighth anniversary of Cancer Drug Resistance (CDR), the journal is pleased to present the latest episode of Research Voices, an interview series spotlighting leading scientific experts and clinical pioneers from around the world.

This episode features Professor A. Thomas Look, a globally recognized leading expert in pediatric oncology from Harvard Medical School and Dana-Farber Cancer Institute.

In this engaging conversation, Prof. Look discusses the profound biological complexities of cancer therapy resistance, emphasizing that relapse is fundamentally an evolutionary process driven by rare, pre-existing mutant subclones. He shares his perspectives on how innovative fun  execute large-scale genetic and drug screens to overcome resistance. Additionally, Prof. Look explores the unique clinical bottleneck of applying precision medicine to “mutationally silent” childhood tumors and outlines his thoughts on targeting core regulatory circuits (CRCs) and utilizing emerging immunotherapies - like HLA-presented CAR-T cells - to achieve durable cures.

Watch the Full Interview

Interview Highlights

• The pioneering discovery of ALK mutations and the evolutionary nature of pre-existing subclonal resistance
• The application and advantages of transgenic zebrafish models in pediatric cancer research and high-throughput drug screening
• The unique clinical challenges of applying precision medicine to "mutationally silent" childhood tumors compared to adult malignancies
• Strategies for targeting Core Regulatory Circuits (CRCs) and traditionally “undruggable” transcription factors like PHOX2B
• The promise of AI-driven drug discovery and HLA-presented CAR-T cell immunotherapies in overcoming resistance

Key Takeaways

Viewing Resistance as an Evolutionary Process

Prof. Look discusses the dynamic and adaptive nature of tumor resistance in clinical settings. He notes that while targeted therapies can yield striking initial tumor regression, this does not necessarily equate to a durable cure. He strongly asserts that because tumors can harbor trillions of cells at diagnosis, rare pre-existing mutant subclones will inevitably survive and expand under treatment pressure. To counteract this, he emphasizes the absolute necessity of employing rational combination therapies from the very beginning to simultaneously block non-cross-resistant evolutionary escape routes.

Advancing High-Throughput Screening with Zebrafish Models

The conversation touches upon the critical evolution of preclinical laboratory models. Prof. Look highlights the cutting-edge development of transgenic and CRISPR-knockout zebrafish models. He explains that these models offer distinct advantages for pediatric research: they share deep genetic conservation with humans and can be bred efficiently in large numbers, making them a uniquely powerful platform for uncovering synergistic drug interactions and investigating the root causes of therapeutic resistance in childhood cancers like neuroblastoma and leukemia.

Overcoming the Barrier of "Mutationally Silent" Pediatric Cancers

Prof. Look reflects on the fundamental biological differences between adult and pediatric tumors. He points out a major challenge for translational translation: childhood cancers have not been exposed to decades of environmental carcinogens and thus lack the actionable point mutations commonly found in adult tumors. To solve this, he underscores the value of targeting master transcriptional networks, such as the adrenergic CRC essential for neuroblastoma survival. While these transcription factors are classically considered "undruggable," he shares exciting prospects for overcoming this limitation via emerging AI-driven molecular targeting and innovative CAR-T cell therapies engineered to recognize internal tumor epitopes presented on the cell surface.

This interview marks a key installment of the Research Voices series. Stay tuned for upcoming conversations with leading experts as we continue to explore the theme Breaking Resistance, Shaping the Future.

Editor: Stella Jin
Language Editor: Amir Khan
Production Editor: Xingyue Luo
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance